Skinvisible (SKVI) Common Equity (2010 - 2026)

Skinvisible (SKVI) has 17 years of Common Equity data on file, last reported at -$10.5 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 11.08% year-over-year to -$10.5 million; the trailing twelve-month figure through Mar 2026 stood at -$10.5 million (down 11.08% YoY), and the FY2025 full-year result was -$10.3 million, down 11.27% from the prior year.
• Common Equity retreated to -$10.5 million in Q1 2026, from -$10.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of -$5.6 million in Q1 2022 to a low of -$10.5 million in Q1 2026.
• A 5-year average of -$8.6 million and a median of -$9.2 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity sank 44.85% in 2023 and retreated 1.39% in 2025, its largest moves.
• Tracing SKVI's Common Equity over 5 years: stood at -$6.6 million in 2022, then tumbled by 35.88% to -$9.0 million in 2023, then retreated by 2.22% to -$9.2 million in 2024, then dropped by 11.27% to -$10.3 million in 2025, then fell by 2.6% to -$10.5 million in 2026.
• Business Quant data shows SKVI's Common Equity at -$10.5 million in Q1 2026, -$10.3 million in Q4 2025, and -$10.0 million in Q3 2025.